The effective expiration of the U.S. patent on Pfizer's (NYSE:PFE) cholesterol-treating Lipitor drug is still months away from happening. However, the planning has already begun at Pfizer - and even more so at the companies ready to step into the fray with a generic version of the drug.

TUTORIAL: The Greatest Investors

As the old saying goes, one man's loss is another man's gain. In this case though, the idea is being applied to pharmaceutical companies. Pfizer's loss could be a major one, considering that the drug translates into about $10 billion in revenue per year for the drug maker - 15% of last year's $68 billion on total revenue for the company with $5.3 billion coming from the United States alone.

Rather than lament the loss of the Lipitor monopoly though, opportunistic investors may want to look at this looming patent expiration from the other side. Who wins? To that end, a handful of details need to be laid out.

Lipitor Replacement Time Frame and Contestants
Due to a quirk in the way drug patent challenges work, a 180-day waiting period means an alternative won't be approved for sale until the end of November. That one is going to be sold by India's Ranbaxy, assuming approval. Ranbaxy would then have another six months of exclusivity to sell its version (the end of May, 2012), and after that, it's game on for anybody who can convince the FDA their version is an acceptable alternative.

Ranbaxy isn't viewed as the long-term generic favorite, though. That honor belongs to a company called Watson Pharmaceutical (NYSE:WPI), which has actually been authorized (not that it needed it) by Pfizer to start selling a generic Lipitor made by Pfizer beginning in June of next year, after Ranbaxy's exclusivity phase ends. In fact, there's even a slim chance that mis-steps from Ranbaxy could open the sales window sooner for Watson.

That said, it's not like patent-loss pain and generic competition hasn't already been felt by Pfizer. The privately-held Canadian company Apotex has already launched an alternative to Lipitor in that country, where Lipitor sales totaled $1.1 billion last year. Merck's (NYSE:MRK) Zocor is very comparable to Lipitor as well. In fact, it's the 2006 loss of the patent on Zocor that may offer the best template for what's about to happen with the patent expiration in Lipitor.

Shape of Things to Come
Though it never really rivaled Lipitor, which has been the best-selling drug of all time, Merck's Zocor was selling at an annual pace of $4.4 billion (globally) before that patent expired. Half a year later, quarterly sales of Zocor had fallen by 65%. The generic version called Simvastatin, manufactured by Teva Pharmaceuticals (Nasdaq:TEVA) through its Ivax subsidiary, had driven sales of Zocor down to $876 million by 2007.

That's clearly good news for Watson, which has done $3.6 billion in sales over the last twelve months. Even at a lower price point, generic Lipitor stands to be a big coup for the company.

On the flip side, Pfizer has even commented that they "expect multi-source generics to arrive on the U.S. markets 180 days after November 30, 2011." So, don't assume Watson, or even Ranbaxy, has the inside track. Indeed, one of the names that has been quietly brought up as a potential manufacturer of generic Lipitor is Teva.

The Bottom Line
The battle for top spot in generic Lipitor sales likely won't get or stay much bigger than a two-horse race, but even splitting a multi-billion-dollar purse between Teva and Watson is a good deal. (For related reading, also check out 6 Drug Companies With Expiring Patents In 2011.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  8. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  9. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  10. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!